Endurant Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Endurant Capital Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-9,185	Closed	-$4.4M	–	40
2023 Q1	$4.4M	Buy	9,185 +5,292	+136%	+$2.48M	2.26%	14
2022 Q4	$1.64M	Sell	3,893 -3,091	-44%	-$1.25M	0.66%	27
2022 Q3	$2.91M	Sell	6,984 -9,044	-56%	-$4.51M	0.95%	27
2022 Q2	$7.93M	Sell	16,028 -1,123	-7%	-$585K	2.78%	14
2022 Q1	$9.66M	Buy	17,151 +2,612	+18%	+$1.57M	2.54%	12
2021 Q4	$11M	Sell	14,539 -3,733	-20%	-$2.79M	2.65%	12
2021 Q3	$13.6M	Buy	18,272 +6,452	+55%	+$4.83M	3.1%	8
2021 Q2	$7.62M	Sell	11,820 -2,964	-20%	-$1.8M	2.09%	16
2021 Q1	$8.44M	Buy	+14,784	New	+$8.75M	2.2%	19
2020 Q4	–	Sell	-3,916	Closed	-$2.02M	–	58
2020 Q3	$2.02M	Buy	3,916 +411	+12%	+$208K	0.6%	44
2020 Q2	$1.58M	Buy	+3,505	New	+$1.55M	0.09%	42
2019 Q4	–	Sell	-6,910	Closed	-$2.3M	–	58
2019 Q3	$2.3M	Buy	6,910 +3,175	+85%	+$1.04M	0.83%	25
2019 Q2	$1.17M	Buy	+3,735	New	+$1.12M	0.46%	42

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Endurant Capital Management's BIO Position: Q2 2023 in Review

Endurant Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2023, closing a stake of 9,185 shares — an estimated $4.4M sold.

Endurant Capital Management first reported a position in BIO in Q2 2019 and held it in 13 quarters. The position peaked at $13.6M in Q3 2021. 469 funds tracked by Wall St. Rank hold BIO as of Q2 2023.

Endurant Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q2 2023 after selling out during the quarter.
Endurant Capital Management sold 9,185 Bio-Rad Laboratories Class A shares in Q2 2023, an estimated $4.4M.
Endurant Capital Management first reported a position in Bio-Rad Laboratories Class A in Q2 2019 and held it in 13 quarters.
Endurant Capital Management's Bio-Rad Laboratories Class A position peaked at $13.6M in Q3 2021.
469 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2023.

Based on Endurant Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.